Incidence and Severity of Ocular TEAEs.
| Group | Value (Participants) |
|---|---|
| Part A Placebo | 3 |
| Part A Elamipretide 1.0% Ophthalmic Solution | 6 |
| Part B Placebo | 1 |
| Part B Elamipretide 3.0% Ophthalmic Solution | 1 |
Trial · Interventional
CompletedPhase 1/2Results postedRegistry dataShort name SPIFD-101
United States
1 trial · 1 completed · 1 with posted results
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal Endothelial Dystrophy (FCED) presenting with mild to moderate corneal edema.
Experimental
Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)
Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
Experimental
Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)
Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
Placebo comparator
Placebo A
Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
Placebo comparator
Part B Placebo
Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
Outcomes the sponsor listed as primary.
Incidence and Severity of Ocular TEAEs.
Time frame · Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
The incidence and severity of ocular treatment emergent adverse events (TEAEs)
The Incidence and Severity of Systemic Adverse Events
Time frame · Screening Visit, Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16
The incidence and severity of systemic treatment emergent adverse events (TEAEs)
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part A
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Number of participants who had a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part A. Part B is reported as separate outcome since unit of measure is number of eyes.
Change From Baseline in Findings From Slit Lamp Examinations (SLE) Part B
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Number of eyes with a change from baseline from normal or abnormal not clinically significant, to abnormal clinically significant (CS) findings for slit lamp examinations (SLE) for Part B. Part A is reported as separate outcome.
Change From Baseline in Intraocular Pressure (IOP) for Part A
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part A
Change From Baseline in Intraocular Pressure (IOP) for Part B
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12 , and Week 16 or early discontinuation visit
Change from Baseline in intraocular pressure (IOP) using Goldmann applanation tonometry for Part B. Part A is reported separately.
Change From Baseline in Central Corneal Thickness by Visit Part A as Measured by Pachymetry for Part A
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16
Change from Baseline in Central Corneal Thickness by Visit as measured by Pachymetry for Part A. Part B is reported as a separate outcome measure.
Central Corneal Thickness Part B
Time frame · Baseline (Day 1), Week 1, Week 4, Week 8, Week 12, and Week 16, or Early discontinuation visit
Central Corneal Thickness: by-subject data as measured by Pachymetry and Pentacam. Part A is reported as a separate outcome measure.
Change From Baseline Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A
Time frame · Baseline, Week 1, 4, 8, and 12
Change From Baseline in Endothelial Cell Hexagonality in Percentage Over All 12 Weeks for Part A. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium. Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells. Histologically, healthy corneal cells initially have a hexagonal shape. As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell. This, in turn, causes the remaining cells to lose their hexagonal shape. Assessments were performed using the flex center and full auto methods for Part A and data from the flex center method was summarized. The flex center method was used for Part B. The percent of Part B is entered as a separate outcome measure. A decrease from baseline in % cell hexagonality means worse outcome, a increase from baseline means better outcome.
Corneal Endothelial Cell Hexagonality Part B
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, and Week 16 or early discontinuation visit
Corneal Endothelial Cell Hexagonality in Percentage by-subject data: Part B. Data was only listed in weeks where images were good enough quality to quantify. Specular microscopy is a noninvasive photographic technique that allows visualization and analyzation the corneal endothelium. Using computer-assisted morphometry, specular microscopes analyzes the size, shape and population of the endothelial cells. Histologically, healthy corneal cells initially have a hexagonal shape. As endothelial cells die, neighboring cells enlarge to cover the empty space once occupied by the cell. This, in turn, causes the remaining cells to lose their hexagonal shape. The flex center method was used for Part B. A decrease in percent of cell hexagonality from baseline means worse outcome, an increase from baseline means better outcome.
Change From Baseline in Best Corrected Visual Acuity (BCVA) Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale for Part A.
Time frame · Baseline, Weeks 1, 4, 8, 12, and 16
Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome). Part B was listed separately.
Best Corrected Visual Acuity (BCVA) Score Using ETDRS Scale for Part B
Time frame · Baseline, Weeks 1, 4, 8, 12, and 16
Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).
Change From Baseline in Endothelial Cell Density Over All 12 Weeks for Part A
Time frame · Baseline, Weeks 1, 4, 8, and 12
Change From Baseline in Endothelial Cell Counts, or density (Counts/mm\^2) over all 12 weeks for Part A. Part B is entered as a separate outcome measure.
Corneal Endothelial Cell Density Part B
Time frame · Baseline, Weeks 1, 4, 8, 12, and 16.
Corneal Endothelial Cell Density: Part B, By-subject data for all time points where images were readable. For all time points where there were "Poor Quality Images" or "too few cells to register", there were no data available, and these were not listed below.
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks for Part A
Time frame · Baseline, Week 12
Change From Baseline in Endothelial Cell Coefficient of Variation Over All 12 Weeks. Coefficient of variation (CV) is Standard deviation (SD) of cell area divided by the mean cell area of endothelial cell analyzed. CV represents the coefficient, or degree, of variation in the sizes of the endothelial cells (polymegethism). By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring. The more variation, the worse the outcome. Part B is is entered as a separate outcome measure.
Coefficient of Variation (CoV) Part B
Time frame · Baseline, Weeks 1, 4, 8,12, and 16
Part B, By-subject data for all time points where images were readable. For all time points where there were "Poor Quality Images" or "too few cells to register" there were no data available. CoV represents the coefficient, or degree, of variation in the sizes of the endothelial cells. By measuring the variation in size between endothelial cells, the system can measure how much cell loss is occurring. A CoV less than 40 is normal.
Change From Baseline in Corneal Area Affected by Microcysts for Part A
Time frame · Baseline, Weeks 1, 4, 8, 12, and 16
Change from Baseline in corneal area affected by microcysts by visit for Part A.
Corneal Area Affected by Microcysts: Part B
Time frame · Baseline, Weeks 1, 4, 8, 12, and 16, or early discontinuation visit
Corneal area affected by microcysts: by-subject data for Part B. No microcysts were present for any timepoints.
Change From Baseline in Corneal Bullae for Part A.
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, Week 16
Count of participants in number, size and location of bullae by treatment. Part B is listed separately.
Corneal Bullae: Part B
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
Number, size and location of Corneal bullae: By-subject data: Part B.
Change From Baseline in Severity of Corneal Stromal Folds for Part A
Time frame · Baseline, Weeks 1, 4, 8, 12, and 16
Change from baseline in severity of corneal stromal folds by visit. Descriptive assessment made by Investigator; severity is not assessed using a scale.
Severity of Corneal Stromal Folds:Part B
Time frame · Baseline, Week 1, 4, 8, 12, and 16, or early discontinuation visit
Severity of corneal stromal folds by-subject data by visit. Descriptive assessment made by Investigator in the following categories: Not present, trace, mild.
Change From Baseline in Contrast Sensitivity (Log Score) for Part A
Time frame · Baseline, Week 1, 4, 8, 12 weeks
Change from Baseline in contrast sensitivity over all 12 weeks log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E. Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values. Lower log scores equals lower contrast sensitivity and worse outcome. Higher log scores mean higher contrast sensitivity and better outcome. For 3cpd, range is 0.7-2.08; 6 cpd: 0.91-2.29; 12 cpd: 0.61-1.99; 18cpd: 0.17-1.55, unless no gratings were visible. If no gratings were visible, .3 log was subtracted from the lowest score for 3, 6, and 12cpd. For 18cpd .01 log was used, or essentially 100% contrast.
Contrast Sensitivity for Part B; By-subject Data
Time frame · Baseline, Week 1, Week 4, Week 8, Week 12, Week 16, or early discontinuation visit
Contrast Sensitivity log score at 3, 6, 12, 18 cycles per degree (cpd) using Vector Vision's CSV-1000E by-subject data, Part B. Part A is listed separately. Standard tables for the VectorVision's CSV-1000E model were used to convert linear results to the log values. Lower log scores equals lower contrast sensitivity and worse outcome. Higher log scores mean higher contrast sensitivity and better outcome. For 3cpd, range is 0.7-2.08; 6 cpd: 0.91-2.29; 12 cpd: 0.61-1.99; 18cpd: 0.17-1.55, unless no gratings were visible. If no gratings were visible, .3 log was subtracted from the lowest score for 3, 6, and 12cpd. For 18cpd .01 log was used, or essentially 100% contrast.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (Participants) |
|---|---|
| Part A Placebo | 3 |
| Part A Elamipretide 1.0% Ophthalmic Solution | 6 |
| Part B Placebo | 1 |
| Part B Elamipretide 3.0% Ophthalmic Solution | 1 |
| Group | Value (Participants) |
|---|---|
| Part A Elamipretide 1.0% Ophthalmic Solution or Placebo | 3 |
| Part B Placebo | 1 |
| Part B Elamipretide 3.0% Ophthalmic Solution | 2 |
| Group | Value (participants) |
|---|---|
| Part A Placebo | 0 |
| Part A Elamipretide 1.0% Ophthalmic Solution | 0 |
| Group | Value (participants) |
|---|---|
| Part B Placebo | 0 |
| Part B Elamipretide 3.0% Ophthalmic Solution | 0 |
| Group | Value (mmHg) | Spread |
|---|---|---|
| Placebo Part A | -0.6 | 0.64 |
| Elamipretide 1.0% Ophthalmic Solution | -0.4 | 0.49 |
| Group | Value (mmHg) | Spread |
|---|---|---|
| Placebo Part B | 3.0 | 0.00 |
| Elamipretide 3.0% Ophthalmic Solution | 0.2 | 3.19 |
| Group | Value (µm) | Spread |
|---|---|---|
| Placebo Eye - Pachymetry | 15.4 | 47.95 |
| Elamipretide 1.0% Ophthalmic Solution Eye-Pachymetry | 7.2 | 19.99 |
| Vehicle Eye-Pentacam | 1.8 | 19.72 |
| Elamipretide 1.0% Ophthalmic Solution-Pentacam | 2.0 | 25.51 |
| Group | Value (µm) |
|---|---|
| OD-Pachymetry | 626 |
| OD Pentacam | 593 |
| OS: Pachymetry | 604 |
| OD-Pentacam | 591.3 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Part A Elamipretide 1.0% Ophthalmic Solution and PlaceboPart A participants includes those receiving 1% Elamipretide in one eye and placebo in other eye. This arm will report systemic events that cannot be attributed to either intervention. | 0 / 18 | 1 / 18 | 7 / 18 |
| Part A Placebo OnlyThese will be reporting ocular AEs for placebo eye only. Part A participants includes those receiving Placebo in one eye only. | 0 / 18 | 0 / 18 | 3 / 18 |
| Part A Elamipretide 1.0% Ophthalmic Solution OnlyThese will be reporting ocular AEs for elamipretide eye only. Part A participants includes those receiving 1% Elamipretide in one eye only. | 0 / 18 | 0 / 18 | 6 / 18 |
| Part B PlaceboPart B participants includes those receiving Placebo in both eyes. This arm will be reporting ocular and systemic events. | 0 / 1 | 0 / 1 | 1 / 1 |
| Part B Elamipretide 3.0% Ophthalmic SolutionPart B participants includes those receiving 3% Elamipretide in both eyes. This arm will be reporting ocular and systemic events. | 0 / 3 | 0 / 3 | 3 / 3 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
No study cites this trial.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated